ReviewFaculty reviews2022
Recent advances in understanding the role of eosinophils.
Review in Faculty reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Redefining Hematology Referral Thresholds for Eosinophilia.European journal of haematology · 2026Review
- Real-World Effectiveness Following Benralizumab Use in Patients with Severe Eosinophilic Asthma in Romania: A Retrospective Cohort Study (BREEZE).Journal of clinical medicine · 2026Article
- The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma.Advances in respiratory medicine · 2025Article
- Constructing a prediction model for acute pancreatitis severity based on liquid neural network.Scientific reports · 2025Article
- Immune responses in children with secondary infection of mycoplasma pneumoniae after COVID-19: focus on eosinophils and IgE.BMC infectious diseases · 2025Observational
- Advancing toward a unified eosinophil signature from transcriptional profiling.Journal of leukocyte biology · 2024Review
- Cardiac Abnormalities in Hypereosinophilic Syndromes.Arquivos brasileiros de cardiologia · 2024Review
- Functional Role of Piezo1 in the Human Eosinophil Cell Line AML14.3D10: Implications for the Immune and Sensory Nervous Systems.Biomolecules · 2024Article
- Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.Journal of leukocyte biology · 2024Review
- Exploration of risk factors and characteristics of COVID-19 infection among patients with hematological malignancies in Suzhou, China: a retrospective study.Frontiers in oncology · 2024Article
- Metabolism in type 2 immune responses.Immunity · 2023Review
- Eosinophils as potential biomarkers in respiratory viral infections.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our understanding of eosinophil biology, development, and regulation has dramatically increased in the past decade, leading to new paradigms for the role of eosinophils in human health and disease and, perhaps more importantly, providing insights toward novel treatment strategies in the fight against eosinophil-mediated inflammation. In this review, we discuss recent advances regarding the role of eosinophils in host-viral defense, eosinophil heterogeneity, and eosinophil-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.